Vision
To translate adult stem cell technology prowess into cancer clinical reality
To translate adult stem cell technology prowess into cancer clinical reality
In June 2017, Transcell shareholders agreed to focus it’s disruptive drug discovery pursuits in Oncology vertical with the team’s early breakthrough data on certain druggable molecules discovered, as a spin-out (Transcell Oncologics). The research on predictive real-time donor and patient-based progenitor cellular platforms dates back to 2013 while access to nature-inspired novel macrocyclic small molecules/toolbox to 2014
Develop all new rational nature-inspired complex architectural, scalable synthesis based, macrocyclic small molecules toolbox and hunt for druggable, selective killers of cancer stem cells
Pursue multi-target activity spaces between druggable molecules and cancer stem cells to develop investigational new drugs (INDs) for cancers